Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 11, 2026

Here’s a List of Gulf Energy Infrastructure Damaged in Iran War

View original at finance.yahoo.com
Here’s a List of Gulf Energy Infrastructure Damaged in Iran War (Bloomberg) -- Dozens of refineries, oil fields, gas plants, ports and other energy infrastructure have been damaged by missile and drone strikes, six weeks since the war began…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Israeli attacks on Lebanon breached the terms of the ceasefire accord

    60% confidence
  • Riyadh refinery attack directly affected exports of refined products to global markets

    60% confidence
  • Extensive recent attacks occurred on Saudi energy facilities

    60% confidence
  • Ruwais refinery suffered multiple fires caused by falling debris from air-defense interception

    60% confidence
  • KNPC and PIC facilities suffered significant damage as emergency and fire response teams worked to contain conflagrations at several sites

    60% confidence

Data points we hold from this source

Exxon Mobil Corporation · ownership stake50 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Here’s a List of Gulf Energy Infrastructure Damaged in Iran War — Source | Via News | ViaNews EU